Adverse Drug Reactions of Dovonex (Calcipotriene) 0.005% Cream
The most common adverse reaction to Dovonex cream is skin irritation, occurring in approximately 10-15% of patients, with additional reactions including rash, pruritus, dermatitis, and worsening of psoriasis in 1-10% of patients 1.
Primary Adverse Reactions
Local Skin Reactions (Most Common)
- Skin irritation: 10-15% of patients - this is the predominant side effect 1
- Transient irritation: Affects both lesional and perilesional skin 2
- Rash: 1-10% of patients 1
- Pruritus (itching): 1-10% of patients 1
- Dermatitis: 1-10% of patients 1
- Worsening of psoriasis: 1-10% of patients 1
Systemic Reactions (Rare but Important)
- Reversible elevation of serum calcium (hypercalcemia): More likely when using >100 g/week 2
- This is a dose-dependent effect requiring monitoring in patients using large quantities
Distinguishing Allergic vs. Irritant Reactions
The vast majority of reactions to calcipotriene are irritant contact dermatitis, not true allergic contact dermatitis 3, 4. Key distinguishing features:
- Irritant reactions: Occur at higher doses, more common, dose-dependent
- Allergic reactions: Rare, occur at lower doses, not dose-dependent 3
- Patch testing shows calcipotriene is a mild irritant of the non-corrosive type, causing redness and edema without impairing the skin barrier 4
Important Drug Interactions and Precautions
Photosensitivity Considerations
- Calcipotriene causes photosensitivity 2
- However, there is no contraindication to combining with UVB phototherapy 2
- Critical timing: Apply calcipotriene after phototherapy treatment to avoid inactivation by UVA radiation and blocking of UVB 5
Incompatible Combinations
- Avoid concurrent use with salicylic acid: The acidic pH inactivates calcipotriene and reduces effectiveness 5
- Avoid concurrent use with lactic acid products: pH incompatibility 2
Safety Profile in Long-Term Use
Long-term use up to 52 weeks has demonstrated excellent safety 5, 2:
- No serious adverse events reported in 52-week studies 5
- No hypothalamic-pituitary-adrenal (HPA) axis suppression 5, 2
- No striae formation 5, 2
- 69-74% of patients achieved clear or almost clear status with once or twice daily application 5, 2
Pregnancy and Nursing Considerations
- Pregnancy Category C 2
- No information on excretion in breast milk 2
- Pregnant and nursing mothers were excluded from clinical studies 2
Combination Product Considerations
When using calcipotriene combined with betamethasone dipropionate, additional corticosteroid-related adverse effects may occur, including 2:
- HPA axis suppression (though not observed in 52-week studies)
- Skin atrophy
- Other high-potency topical corticosteroid effects
However, the 52-week study with combination therapy showed no drug-related serious adverse events when used on an as-needed basis 2.
Clinical Pearls
- The irritation is typically transient and mild 2
- Adverse drug reactions were comparable to vehicle in maintenance studies (11.3% vs 8.6%) 6
- The ointment vehicle itself may cause some skin barrier impairment with increased transepidermal water loss 4
- Calcipotriene is generally well tolerated with minimal side effects, making it suitable for long-term management 5, 7